A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug.

Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Raltegravir (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms BENCHMRK-2
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jul 2012 5-Year results from a pooled analysis of BENCHMRK I and II presented at the 19th International AIDS Conference.
    • 22 Jul 2012 Five-year results have been presented at the 19th International AIDS Conference according to a Merck media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top